Endogenous Interleukin 4 Is Required for Development of Protective CD4+ T Helper Type 1 Cell Responses to Candida albicans

By Antonella Mencacci,* Giuseppe Del Sero,* Elio Cenci,* Cristiana Fè d'Ostiani,* Angela Bacci,* Claudia M ontagnoli,* Manfred Kopf,‡ and Luigina Romani*

From the *Microbiology Section, Department of Experimental Medicine and Biochemical Sciences, University of Perugia, 06122 Perugia, Italy; and ‡The Basel Institute for Immunology, CH-4055 Basel, Switzerland

Summary

Interleukin (IL)-4–deficient mice were used to assess susceptibility to systemic or gastrointestinal Candida albicans infections, as well as parameters of innate and elicited T helper immunity. In the early stage of systemic infection with virulent C. albicans, an unopposed interferon (IFN)-γ response renders IL-4–deficient mice more resistant than wild-type mice to infection. Yet, IL-4–deficient mice failed to efficiently control infection in the late stage and succumbed to it. Defective IFN-γ and IL-12 production, but not IL-12 responsiveness, was observed in IL-4–deficient mice that failed to mount protective T helper type 1 cell (Th1)-mediated acquired immunity in response to a live vaccine strain of the yeast or upon mucosal immunization in vivo. In vitro, IL-4 primed neutrophils for cytokine release, including IL-12. However, late treatment with exogenous IL-4, while improving the outcome of infection, potentiated CD4+ Th1 responses even in the absence of neutrophils. These findings indicate that endogenous IL-4 is required for the induction of CD4+ Th1 protective antifungal responses, possibly through the combined activity on cells of the innate and adaptive immune systems.
these mice to successfully control the infection in the early stage but not the late, IL-4 being required for induction of protective CD4+ Th1 anticandidal responses.

Materials and Methods

Mice Breeding pairs of homozygous IL-4-deficient (IL-4−/−) and control (IL-4+/+) BALB/c mice (23) were bred under specific, pathogen-free conditions. Mice of both sexes, 8–10 wk old, were used. Procedures involving animals and their care were conducted in conformity with national and international laws and policies.

Yeast infection. In Vivo Analysis, and Treatments. The origin and characteristics of the C. albicans highly virulent CA-6 strain and the live vaccine strain PCA-2 used in this study have already been described in detail (4–13). For infection, cells were washed twice in saline, and diluted to the desired density to be injected intravenously via the lateral tail vein in a volume of 0.5 ml/mouse or intragastrically via an 18-gauge 4-cm-long plastic catheter, as described (24). The viability of the cells was >95% by trypan blue exclusion and quantitative cultures. Quantification of yeast cells in organs of infected mice (6–8/group) was performed by a plate-dilution method, using Sabouraud dextrose agar, and results (mean ± SEM) were expressed as CFU per organ. Resistance to reinfection was assessed by injecting mice with 106 CA-6 cells intravenously, 14 d after primary infection. Mice succumbing to yeast challenge were routinely necropsied for histopathological analysis of disseminated candidiasis. Recombinant murine IL-4 (provided by Dr. R. Robert Coffman, DNA A Research Institute, Palo Alto, CA) was given intraperitoneally together with the anti–IL-4 mAb 11B11 hybridoma (American Type Culture Collection, Rockville, MD; 3 µg IL-4/mouse 2 d before infection. Endotoxin was removed from all solutions prepared by mixing equal volumes of sulfanilamide (1.5% in 1 N HCl) and naphthylethylene diamine dihydrochloride (0.15% in H2O) (Sigma Chemical Co.). A volume of 100 µl of reagent was mixed with 100 µl of supernatant and incubated for 30 min in the dark. Absorbance of the chromophore formed was measured at 540 nm in an automated microplate reader. The data represent the means ± SE of quadruplicate determinations and are expressed as µg NO2−/ml.

Preparation and Reverse Transcription PCR. Splenic macrophages, peritoneal neutrophils, and CD4+ splenocytes were subjected to RNA extraction by the guanidium thiocyanate-phenol-chloroform procedure, as described (28). In brief, 3 µg of total RNA was incubated with 0.5 µg of oligo(dT) (Pharmacia Biotech AB, Uppsala, Sweden) for 3 min at 65°C and chilled on ice for 5 min. Each sample was then incubated for 2 h at 42°C after adding 20 U RNAse inhibitors (Boehringer Mannheim, Mannheim, Germany), 1.5 mM deoxynucleoside triphosphates, 25 U avian myeloblastosis virus reverse transcriptase (RT) (Boehringer Mannheim), and RT buffer (50 mM Tris-HCl, pH 8.3, 8 mM MgCl2, 30 mM KCl, and 10 mM dithiothreitol, final concentrations) in a final volume of 20 µl. cDNA was diluted to a total volume of 500 µl with TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0) and frozen at −20°C until use. Amplification of synthesized cDNA from each sample was carried out as described previously (29). In brief, 5 µl of cDNA was added to a reaction mixture containing 50 mM KCl, 10 mM Tris-HCl, pH 8.3, 3.0 mM MgCl2, 0.01% gelatin, 0.2 mM deoxynucleoside triphosphates, 1 µM of each primer, and 2.5 U AmpliTaq polymerase (PerkinElmer Corp., Hayward, CA). Each 100-µl sample was overlaid with 75 µl mineral oil (Sigma Chemical Co.) and incubated in a
DNA Thermal Cycler 480 (Perkin-Elmer Corp.) for a total of 30–35 cycles for each cytokine. For hypoxanthine-guanine phosphoribosyl transferase (HPRT) and IL-12, the positive controls were obtained through the courtesy of Dr. Giorgio Trinchieri (Wistar Institute, Philadelphia, PA). For IL-4R, the sequences of 5′ sense primers and 3′ antisense primers for IL-12Rβ1 and IL-12Rβ2 were as follows: 5′-GAA CCA CAC ACA CTG TAC CCT G, 3′-TTT AGT GGG CAC GAG CC; IL-12p40, 5′-CAA GAC ATC GAC TAT GAC AGA C, 3′-GTG CTG TCG AGT CTC G. For IL-12Rβ1 and β2, each cycle consisted of 1 min at 94°C, 1 min at 60°C, and 1 min at 72°C. The positive controls were obtained through the courtesy of Dr. Giorgio Trinchieri (Wistar Institute, Philadelphia, PA). For IL-4R, the sequences of 5′ sense primers and 3′ antisense primers were as follows: 5′-TGT GAC CTACAA GGA ACC CA, 3′-GCA AAA CAA CGG GAT GCA GA. For IL-4R, each cycle consisted of 1 min at 94°C, 1 min at 60°C, and 1 min at 72°C. The HPRT primers were used as a control for both reverse transcription and the PCR reaction itself, and also for comparing the amount of products from samples obtained with the same primer. The PCR fragments were analyzed by 1.5% agarose gel electrophoresis and visualized by ethidium bromide staining. PCR-assisted competitive RT-PCR. The semiquantitative competitive PCR developed by Reiner et al. (30), was performed using the competitor construct containing sequences for multiple cytokines, the primers for HPRT and IFN-γ, and the PCR conditions described by the authors. In brief, aliquots of cDNA were assayed for levels of HPRT by placing serial dilutions from 1:1 to 1:40 of the experimental cDNA against a fixed concentration of the competitor construct and examining the ratio of competitor/wild-type band intensity after amplification with HPRT-specific primers. Adjustments were made in the amount of cDNA needed to standardize the HPRT levels to comparable levels among all groups. Serial dilutions of these adjusted volumes of cDNA were then used to quantitate cytokine levels using a fixed concentration of competitor (3 and 1.5 pg/ml for HPRT and IFN-γ, respectively) in each reaction in the presence of cytokine-specific primers. The PCR products were separated by electrophoresis in 2% agarose gels containing ethidium bromide. The point of equivalence in intensity between the competitor (upper band) and the cDNA (lower band) indicates the relative concentration of mRNA.

Statistical Analysis. Survival and organ clearance data from each group of wild-type mice were compared with those from IL-4-deficient mice using the Mann-Whitney U test; P < 0.05 was considered significant. Student’s t test was used to determine statistical significance between cytokine production of the two groups. In vivo groups consisted of four to six animals. The data reported are pooled from three experiments.

**Results**

IL-4−/− Mice Successfully Control C. albicans Infection in the Early Stage, but Susceptible to Infection in the Late Stage. IL-4−/− and IL-4+/+ mice were injected intravenously with different doses (10^6, 5 × 10^5 and 2 × 10^5) of highly virulent CA-6, with 10^6 cells of the live vaccine strain PCA-2, or intragastrically with 10^6 CA-6. Mice were monitored for resistance to primary and secondary infections (Table 1) and for fungal growth in the organs (Fig. 1). The results show that, although the median survival time (MST) of mice injected with the highest inoculum of CA-6 did not differ between the two types of mice, IL-4-deficient mice were more resistant than IL-4+/+ to the lower inocula of the yeast, as observed by the increased survival. IL-4−/− mice were as resistant as wild-type mice to infection with PCA-2 or to intragastric infection with CA-6. However,

### Table 1. Susceptibility of IL-4−/− and IL-4+/+ Mice to C. albicans Infection

| Mice     | Yeast | Dose | Route | MST | D/T | Yeast | Dose | Route | MST | D/T |
|----------|-------|------|-------|-----|-----|-------|------|-------|-----|-----|
| IL-4−/−  | CA-6  | 10^6 | i.v.   | 4   | 8/8 | -     | -    | -     | -   | -   |
|          | CA-6  | 5 × 10^5 | i.v.   | 16^t| 8/8 | -     | -    | -     | -   | -   |
|          | CA-6  | 2 × 10^5 | i.v.   | >60^t| 0/8 | CA-6  | 10^6 | i.v.   | 5.5 | 4/4 |
|          | CA-6  | 10^6  | i.g.   | >60  | 0/8 | CA-6  | 5 × 10^5 | i.v. | 10 | 4/4 |
| PCA-2    | CA-6  | 10^6  | i.v.   | >60  | 0/12| CA-6  | 10^6  | i.v.   | 6   | 6/6 |
| IL-4+/+  | CA-6  | 10^6  | i.v.   | 5   | 12/12| -     | -    | -     | -   | -   |
|          | CA-6  | 5 × 10^5 | i.v.   | 7   | 8/8 | -     | -    | -     | -   | -   |
|          | CA-6  | 2 × 10^5 | i.v.   | 15  | 8/8 | -     | -    | -     | -   | -   |
|          | CA-6  | 10^6  | i.g.   | >60  | 0/12| CA-6  | 5 × 10^5 | i.v. | 21  | 6/6 |
| PCA-2    | CA-6  | 10^6  | i.v.   | >60  | 0/12| CA-6  | 10^6  | i.v.   | >60 | 0/6 |

*Surviving mice were reinfected 14 days after the primary challenge.*

i.g., intragastric; MST, median survival time (d); D/T, dead animals over total mice infected.

*Statistical significance between cytokine production of the two groups.*
of infection with either $5 \times 10^5$ or $2 \times 10^5$ CA-6 cells. However, at 14 d after infection, when no yeast cells were recovered in mice surviving the lowest inoculum, an extensive fungal growth was observed in the kidneys of mice succumbing to infection. In contrast, the fungal load in the kidneys of wild-type mice was always higher and increased continuously until death. In mice with gastrointestinal infection, the number of yeast cells recovered from the stomach was significantly lower in IL-4$^{-/-}$ than in IL-4$^{+/+}$ mice, even though both types of mice eventually survived the infection. Resistance to CA-6 intravenous reinfection was lower in IL-4$^{-/-}$ than IL-4$^{+/+}$ mice, as revealed by the high number of yeast cells recovered from the kidneys of IL-4$^{-/-}$ reinjected mice. Histopathological examination of the kidneys of systemically infected IL-4-deficient mice revealed patterns of lesions similar to those observed in resistant or susceptible strains of mice infected intravenously (3–5), with signs of extensive fungal growth and numerous foci of inflammatory reaction (mainly consisting of polymorphonuclear cells) throughout the kidney parenchyma of mice succumbing to infection and absence of pathological lesions and fungal growth in kidneys of mice resistant to infection (data not shown). Therefore, these data clearly show a two-stage control of C. albicans infection in mice. IL-4-deficient mice were highly resistant in the early stage of infection, but highly susceptible in the late stage.

Early control of C. albicans infection in IL-4$^{-/-}$ mice is associated with unimpaired antifungal activity of phagocytic cells. To evaluate the contribution of cells of the innate immune system on the ability of IL-4-deficient mice to efficiently oppose infectivity in the early stage of infection, the antifungal effector functions of macrophages and neutrophils were assessed. Splenic macrophages and peritoneal neutrophils were obtained from IL-4$^{-/-}$ and $^{+/+}$ mice at 3 d after intravenous infection with $5 \times 10^5$ CA-6 cells and assessed for candidacidal activity and production of NO. The results (Table 2) showed that the candidacidal activity of both types of cells was severely depressed in IL-4$^{-/-}$ mice upon infection, as opposed to the unimpaired activity of those

![Figure 1](image-url)  

**Figure 1.** Fungal growth in the organs of IL-4$^{-/-}$ and IL-4$^{+/+}$ mice injected with $5 \times 10^6$ (solid column) or $2 \times 10^6$ (dotted column) CA-6 cells (Systemic infection) or $10^8$ CA-6 cells (Gastrointestinal infection). Enumerating yeast cells recovered from the kidneys of mice with systemic infection or from the stomach and kidneys of mice with gastrointestinal infection was performed at different days after infection. In the gastrointestinal infection, yeast cell counts in the kidneys were performed 4 d after intravenous reinfection with $5 \times 10^6$ CA-6. Cumulative data from two experiments (mean = SE, four to six animals per group). Vertical bars, upper limit of the standard error; *, no viable yeast units found. For each CFU value, $P < 0.05$ (Student's t test, IL-4$^{-/-}$ versus IL-4$^{+/+}$ mice).

### Table 2. Candidacidal Activity and NO$_2^-$ Production by M acrophages and N eutrophils from IL-4$^{-/-}$ and IL-4$^{+/+}$ Mice Infected with C. albicans

| Cells* | Infection        | IL-4$^{-/-}$ | IL-4$^{+/+}$ | IL-4$^{-/-}$ | IL-4$^{+/+}$ |
|--------|------------------|--------------|--------------|--------------|--------------|
|        |                  | %            | %            | $\mu g/ml$   | $\mu g/ml$   |
| M acrophages | N one   | 51 ± 4        | 33 ± 4       | 1.4 ± 0.5    | 2.6 ± 1.1    |
|         | CA-6    | 53 ± 5        | 20 ± 3       | 7.1 ± 1.1    | 3.8 ± 2.0    |
| N neutrophils | N one   | 68 ± 6        | 60 ± 5       | 10.2 ± 3.1   | 9.0 ± 3.1    |
|         | CA-6    | 68 ± 5        | 14 ± 2       | 10.6 ± 2.5   | 11.2 ± 3.2   |

*$^*$M acrophages were from the spleens and neutrophils from the peritoneal cavity of mice uninfected or infected with $5 \times 10^5$ CA-6 cells 3 d before.

$^\dagger$M acrophages and neutrophils were incubated with C. albicans at a cell/cell ratio of 5:1 for 4 and 1 h, respectively, before evaluation of Candida growth inhibition activity.

$^\ddagger$Nitrate determination in supernatants from cells cultured as in $^\dagger$ was assessed by a standard Griess reaction, as detailed in Materials and Methods.
from IL-4−/− mice. Interestingly, the candidacidal activity of macrophages, and lesser that of neutrophils, appeared to be higher in uninfected IL-4−/− mice as opposed to wild-type mice. Likewise, production of NO occurred successfully in IL-4-deficient mice, and to a lesser extent in wild-type mice. Moreover, the number of peripheral white blood cells did not differ between IL-4−/− and IL-4+/+ uninfected mice and increased comparably upon infection (data not shown). Therefore, these data suggest that a successful innate antifungal immune response occurs in IL-4−/− mice upon infection.

Susceptibility of IL-4−/−. Mice to C. albicans Is Associated with Impaired Development of Antifungal CD4+ Th1 Responses. IFN-γ is a potent activator of antifungal effector functions of phagocytic cells (31, 32) and is produced by a variety of cells, including NK and CD4+ Th1 cells (33). Therefore, we assessed the level of IFN-γ production in cultures of unfractionated or purified CD4+ T splenocytes obtained from mice infected with 5 × 10^8 CA-6 cells, soon after infection. We also extended the analysis to IL-2, IL-4, and IL-10 production, as resistance and susceptibility to C. albicans is associated with preferential expansion of cells producing Th1 and Th2 cytokines, respectively (1, 2). We found that production of IFN-γ by mitogen-stimulated splenocytes was higher in IL-4−/− than +/+ mice, either uninfected or at 3 d after infection, at a time when no IL-4 or minimal IL-10 were detected in the former mice compared to wild-type mice (Fig. 2). On assaying cytokine levels produced by antigen-stimulated CD4+ T splenocytes, a similar pattern of Th1 cytokine production was observed in IL-4−/− and +/+ mice, in that minimal or no IFN-γ and IL-2 were produced. As expected, IL-4 and IL-10 productions were increased in infected wild-type mice, as opposed to no (IL-4) or minimal (IL-10) detection in mutant mice (Fig. 2). Therefore, these data indicated that the early sustained production of IFN-γ in IL-4−/− mice was derived from cells other than CD4+ Th1 lymphocytes.

To investigate whether CD4+ Th1 development may occur in IL-4-deficient mice, we measured cytokine production in culture supernatants of purified CD4+ splenocytes from IL-4-deficient mice infected under conditions that would otherwise result in the activation of protective CD4+ Th1s. For this purpose, cytokine production by splenic CD4+ T cells was assessed in mice reinfected with virulent CA-6, 14 d after the primary intravenous challenge with PCA-2 or after the primary intragastric challenge with CA-6. The results showed (Fig. 3) that production of IFN-γ and IL-2 were elevated, as expected, in IL-4+/+ mice either surviving reinfection or showing increased resistance to it (Table 1). In contrast, minimal production of both cytokines was observed in IL-4 mutant mice, succumbing to reinfection. We also assessed levels of IFN-γ gene expression in CD4+ T cells from both types of mice by competitive PCR. IL-4−/− and IL-4+/+ mice were infected with PCA-2 cells and assessed for IFN-γ gene expression 3 d after reinfection with CA-6 cells. The results showed a three- to fourfold increase in the IFN-γ message in CD4+ cells from wild-type as compared to mutant mice (Fig. 4). Interestingly, treatment with exogenous IL-4 restored IFN-γ gene expression to a level comparable to that observed in wild-type-resistant mice.

IL-12 Production, but Not IL-12 Responsiveness, Is Impaired in IL-4−/− Mice Infected with C. albicans. Because IL-12 is both required and prognostic for Th1 development in mice with candidiasis (9, 10), we evaluated whether the failure of IL-4-deficient mice to default to the Th1 pathway was as
been to supply mice with exogenous IL-12. However, due to an adverse effect on neutrophils (11), administration of exogenous IL-12 to mice with candidiasis does not have a beneficial effect (9, 11). Nevertheless, the finding that in vitro exposure to IL-12 greatly increased production of IFN-\(\gamma\) by CD4+ T cells from IL-4−/− mice cultured with Candida Ag and accessory cells (data not shown), indicated that the defective production of IL-12 may be a limiting factor in the induction of CD4+ Th1 responses in IL-4−/− deficient mice.

IL-4 Induces IL-12 Production in Response to C. albicans. To assess whether IL-4 would directly induce production of IL-12 in mice with candidiasis, we evaluated the effect of IL-4 priming on the ability of neutrophils and macrophages to release immunomodulating cytokines, including IL-12. Elicited peritoneal neutrophils and macrophages from IL-4-deficient mice were exposed in vitro to IL-4 before assessing cytokine levels produced in response to yeast cells. The results showed that priming with IL-4 greatly increased the ability of neutrophils, but not of macrophages, to release IL-12, with the levels of production being similar to those observed in IL-4+/+ mice (Fig. 6A). Interestingly, priming with IL-4 increased IL-6 production from both types of cells. The potent stimulatory effect on
neutrophils appeared to be due to a direct effect of IL-4 on these cells. In fact, expression of IL-4R in response to Candida cells was induced by priming with IL-4 as opposed to what observed in macrophages, whose IL-4R expression appeared to be decreased upon IL-4 priming (Fig. 6 B). The same potentiating effect was observed by adding IL-4 and yeast cells simultaneously (data not shown). These data suggest that IL-4 may be required for an optimal production of IL-12 by neutrophils in mice with candidiasis.

Late Treatment with Exogenous IL-4 Increased Th1-mediated Anticandidal Resistance in IL-4−/− Mice. We have already shown that IL-4 production late in infection is associated with the detection of protective CD4+ Th1s and is positively regulated by IL-12 (13). Neutralization, but not administration, of IL-4 late in the course of infection alters an already established CD4+ Th1 response to C. albicans (13). Here we show that treatment with IL-4 early in the course of infection greatly exacerbated the infection in both IL-4−/− and +/+ mice (data not shown), as expected (12). Late treatment with IL-4 greatly increased resistance of PCA-2–infected mutant mice to reinfection, as revealed by increased survival, decreased fungal growth in the kidneys at 3 d after reinfection (Fig. 6 A and B). These data suggest that IL-4 may be required for an optimal production of IL-12 by neutrophils in mice with candidiasis.

**Table 3.** Late IL-4 Administration Restores Resistance and CD4+ Th1 Cytokine Production in C. albicans–infected IL-4−/− Mice

| Mice* | Treatment† | CFU × 10⁹ | Cytokine production‡ |
|-------|------------|------------|---------------------|
|       | rIL-4 mAb Anti-Ly6G mAb Anti-IL-4 | MST | IFN-γ (ng/ml) | IL-2 (U/ml) |
| IL-4−/− | − | − | − | 7 | 1,220 ± 89 | <0.1 | 64 ± 5 |
| IL-4−/− | + | − | − | 27† | 360 ± 65† | 78 ± 10 | 156 ± 14 |
| IL-4−/− | − | + | − | 4 | 3,530 ± 148 | 19 ± 3 | 50 ± 8 |
| IL-4−/− | + | + | − | 11† | 1,047 ± 111† | 48 ± 8 | 144 ± 28 |
| IL-4−/+ | − | − | − | >60 | 225 ± 81 | 81 ± 13 | 187 ± 17 |
| IL-4−/+ | − | + | − | >60 | 304 ± 102 | 119 ± 12 | 148 ± 24 |
| IL-4−/+ | − | − | + | 21** | 581 ± 94 | 24 ± 3 | 89 ± 9 |
| IL-4−/+ | − | + | − | 5 | 2,824 ± 177 | 29 ± 4 | 66 ± 10 |
| IL-4−/+ | + | + | − | 14† | 811 ± 79† | 54 ± 2 | 104 ± 15 |

* Mice were infected intravenously with 10⁶ PCA-2 and reinfeected 14 d later with 10⁶ CA-6.
† Treatment with rIL-4 (12 μg total dose, given together with the 11B11 anti-IL-4 mAb) or with the 11B11 mAb (2 mg, total dose) was done every other day from 6 to 12 d after primary PCA-2 infection. The neutrophil-depleting mAb (anti-Ly6G) was given intraperitoneally (100 μg/mouse) 2 d before reinfection. Neutrophil-depleted mice were treated twice with rIL-4 (as above) 2 and 1 d before reinfection.
‡ Colony forming units in the kidneys at 3 d after reinfection.
§ Cytokine contents of supernatants of CD4+ T cells from spleens of 3-d reinjected mice cultured in vitro with C. albicans antigen and accessory macrophages.

**P < 0.05 Student’s t test (rIL-4-treated versus untreated mice).
**P < 0.05 Student’s t test (anti-IL-4 mAb-treated versus untreated IL-4−/+ mice).
deficient mice infected with a variety of pathogens, which responses in candidiasis. A similar finding was observed in IL-4–

tiation decreased resistance and production of IFN-

that depletion but not administration of IL-4 late in infec-

the expression of protective, Th1-mediated resistance, and IL-4 occurred in mice with candidiasis concomitantly with

However, the subsequent finding that peak production of

conclude that the occurrence of Th1 or Th2 responses pos-

sponses. Previous studies demonstrating the beneficial (4, 5)

produced in IL-4

that signals through the IL-4R

important cytokine in the induction of CD4

Th1 re-

Th2 re-

mice upon infection (data shown). Also, the message of IL-13 was only transiently in-

C. albicans

impaired Th2 response, did not default to the Th1 path-

mechanisms other than those regulating IL-12

Discussion

The results of the present study reveal a novel, previously

unappreciated, role for IL-4 in vivo in mice with C. albicans infection, in which endogenous IL-4 is required for the induction of protective antifungal CD4

Th1 responses. Previous studies demonstrating the beneficial (4, 5) or detrimental (12) effect of early IL-4 neutralization or admin-

istration, respectively, in mice with candidiasis led us to conclude that the occurrence of Th1 or Th2 responses positively correlated with the presence or the absence of IL-4. However, the subsequent finding that peak production of IL-4 occurred in mice with candidiasis concomitantly with the expression of protective, Th1-mediated resistance, and that depletion but not administration of IL-4 late in infection decreased resistance and production of IFN-γ and IL-12, suggested that IL-4 may have a positive effect in C. albicans infection, at least in the late stage (13). In the present study, we found that IL-4-deficient mice, while having an impaired Th2 response, did not default to the Th1 pathway, thus becoming highly susceptible in the late stage of C. albicans infection. Susceptibility to infection was not associated with signs of Th2 activation, such as production of IL-10 and high levels of circulating specific IgE (data not shown). Also, the message of IL-13 was only transiently in-

duced in IL-4−/− and IL-4+/+ mice upon infection (data not shown), thus ruling out the possibility that IL-13, which signals through the IL-4Rα chain (36), may compensate for IL-4 deficiency. Therefore, IL-4 is the most important cytokine in the induction of CD4

Th2 responses in candidiasis. A similar finding was observed in IL-4-deficient mice infected with a variety of pathogens, which have impaired Th2 responses but enhanced (23, 37-41) or not (14, 42) Th1 responses. We found that production of IFN-γ by CD4

Th splenocytes was reduced in IL-4−/− mice compared to wild-type mice in response to virulent C. albicans, but also in experimental conditions of infection that otherwise result in the induction of CD4

Th1. Defective activation of CD4

Th1 was not associated with defective IL-12 responsiveness, as the expression of IL-12Rβ2s on these cells was not different from that observed in wild-type mice mounting a CD4

Th1 response. Therefore, these data indicate that the unimpaired expression of IL-12Rβ2 on CD4

cells, due to the lack of inhibitory IL-4 (34, 35), may not correlate with the functional activation of CD4

Th1s in murine candidiasis.

The results obtained in the present study clearly evidence a two-stage control of infection in mice with C. albicans infection. In the early stage, an innate immune response, if unopposed, may successfully control infectivity in the absence of a supportive CD4

Th1 response, as observed in IL-4-deficient mice exposed to low or moderate yeast inocula or with gastrointestinal infection. In this condition, IFN-γ derived from a non-T cell compartment, presumably N K cells (33), represents one possible activator of antifungal effector cells (31, 32). However, in the late stage of infection, IL-12 and CD4

Th1s producing IFN-γ are required to cope successfully with the pathogen. Indeed, IL-4−/− mice failed to develop protective CD4

Th1 responses, as observed upon intravenous or mucosal immunization, thus becoming susceptible to infection at the late stage. Although IL-4-deficient mice appeared to be resistant to mucosal infection, the data of the present paper do not seem to suggest a possible late exacerbation of the infection, a finding compatible with the notion that IL-4 may mediate both protection (43) and pathology (44) at the mucosal level.

IL-4 appears to be required for the optimal occurrence of both innate and adaptive immune responses. Fungal elimination in IL-4−/− BALB/c mice was not as efficient as in genetically resistant similarly infected mice (our unpublished observation), thus suggesting that IL-4 may exert a positive effect on the antifungal effector function of phago-

cytic cells. In this regard, IL-4 has been reported to enhance murine macrophage mannose receptor activity (45) and to stimulate phagocytosis and killing of yeast cells by macrophages (46) and neutrophils (47). Both types of cells express surface receptors for IL-4 (48, 49). We have previously reported that IL-4 inhibits candidacidal activity and NO release by macrophages (27), and in the present study we found that both activities were unimpaired in IL-4-deficient mice. It is likely that IL-4 may both positively and negatively affect the antifungal effector functions of phago-

cytic cells, the net result being dependent on the dose and time of infection, as observed in leishmaniasis (50).

Whatever the effect of IL-4 on the antifungal effector functions of phagocytic cells, in this study we found that IL-4 efficiently primed neutrophils for IL-12 production in response to the fungus. The effect was associated with the induction of IL-4R on these cells. That IL-4 can prime for IL-12 production has already been observed (51, 52). In human mononuclear cells (51) the positive effect of IL-4
priming on IL-12 production appeared to be due to IL-10 inhibition. Because neutrophils produce IL-12 and IL-10 in response to C. albicans (25, 26), this mechanism could be at work in our system. Interestingly, priming with IL-4 also resulted in the release of high levels of IL-6, which is known to regulate IL-4 receptors on murine myeloid progenitor cells (53). Therefore, it appears that a positive amplification loop exists between IL-6 and IL-4 at the level of neutrophil response, which may be one possible mechanism underlying the beneficial effect of IL-6 in mice with candidiasis (54).

The defective production of IL-12 may likely contribute to the impairment of CD4+ Th1 development in IL-4-deficient mice with C. albicans infection, as it has been shown that exposure to IL-12 restores IFN-γ production in CD4+ T cells from IL-4−/− mice (22). However, the ability of IL-4 to increase IFN-γ and IL-2 production in the relative absence of neutrophils also suggests a possible direct effect of IL-4 on effector Th1s. Elegant studies by Flavell et al. have recently shown that developing Th1 lineage cells produce low levels of IL-4 as they differentiate into Th1 effectors (20, 21), thus implying that endogenous IL-4 could play an essential role in modulating Th1 effectors (20–22). Further studies will elucidate the important role of endogenous IL-4 in CD4+ Th1 differentiation and maintenance in C. albicans infection.

One interesting and still partially unresolved issue raised by our studies is where does IL-4 come from and which yeast/host factors regulate its production in mice with C. albicans infection. Evidence indicates that TCR-α/β+ cells, with an activated phenotype and a biased Vβ receptor expression, are the early producers of IL-4 in infected mice (55). The interaction between C. albicans cells and/or fungal products with cells producing IL-4 appears to occur through a superantigen-like mediated mechanism (55, 56). Whether the late peak production of IL-4 occurring in mice with candidiasis also occurs in recognition of superantigen-like molecules produced by fungal processing or fungal growth polymorphism remains an interesting possibility. Late peak production of IL-4 has also been observed in resistant mice infected with Leishmania major, and appears to be an essential component of the immune response to this parasite (57, 58).

In conclusion, this study provides several novel features of the immune response to C. albicans, including a physiologic role for IL-4 in the induction and maintenance of IL-12-dependent protective cell-mediated immunity.

The authors are grateful to Eileen Mahoney Zannetti for dedicated secretarial and editorial assistance.

This study was supported by AIDS Project 50A.0.28, Italy. The Basel Institute of Immunology has been founded and is supported by Hoffmann-LaRoche.

Address correspondence to Luigina Romani, Microbiology Section, Department of Experimental Medicine and Biochemical Sciences, University of Perugia, Via del Giochetto, 06122 Perugia, Italy. Phone: 39-75-585-3411; Fax: 39-75-585-3400; E-mail: lromani@unipg.it

Received for publication 11 July 1997 and in revised form 15 October 1997.

References

1. Romani, L., P. Puccetti, and F. Bistoni. 1996. Biological role of Th cell subsets in candidiasis. Chem. Immunol. 63:115–137.
2. Puccetti, P., L. Romani, and F. Bistoni. 1995. A Th1/Th2-like switch in candidiasis: new perspectives for therapy. Trends Microbiol. 3:237–240.
3. Romani, L., A. Mencacci, E. Cenci, R. Spaccapelo, P. Mosci, P. Puccetti, and F. Bistoni. 1993. CD4+ subset expression in murine candidiasis. Th responses correlate directly with genetically determined susceptibility or vaccine-induced resistance. J. Immunol. 150:925–931.
4. Romani, L., A. Mencacci, U. Grohmann, S. Mocci, P. Mosci, P. Puccetti, and F. Bistoni. 1992. Neutralizing antibody to interleukin-4 induces systemic protection and Th helper type 1-associated immunity in murine candidiasis. J. Exp. Med. 176:19–25.
5. Puccetti, P., A. Mencacci, E. Cenci, R. Spaccapelo, P. Mosci, K.-H. Enssle, L. Romani, and F. Bistoni. 1994. Cure of murine candidiasis by recombinant soluble interleukin-4 receptor. J. Infect. Dis. 169:1325–1331.
6. Romani, L., E. Cenci, A. Mencacci, R. Spaccapelo, U. Grohmann, P. Puccetti, and F. Bistoni. 1992. Gamma interferon modifies CD4+ subset expression in murine candidiasis. Infect. Immun. 60:4950–4952.
7. Spaccapelo, R., L. Romani, L. Tonnetti, E. Cenci, A. Mencacci, R. Tognellini, S.G. Reed, P. Puccetti, and F. Bistoni. 1995. TGF-β is important in determining the in vivo susceptibility or resistance in mice infected with C. albicans. J. Immunol. 155:1349–1360.
8. Romani, L., P. Puccetti, A. Mencacci, E. Cenci, R. Spaccapelo, L. Tonnetti, U. Grohmann, and F. Bistoni. 1994. Neutralization of IL-10 up-regulates nitric oxide production and protects susceptible mice from challenge with C. albicans. J. Immunol. 152:3514–3521.
9. Romani, L., A. Mencacci, L. Tonnetti, R. Spaccapelo, E. Cenci, P. Puccetti, S.F. Wolf, and F. Bistoni. 1994. Interleukin-12 is both required and diagnostic for murine candidiasis. J. Immunol. 153:5167–5175.
10. Romani, L., A. Mencacci, L. Tonnetti, R. Spaccapelo, E. Cenci, S. Wolf, P. Puccetti, and F. Bistoni. 1994. Interleukin-12 but not interferon-γ production correlates with induction of Th helper type-1 phenotype in candidiasis. Eur. J. Immunol. 22:909–915.
11. Romani, L., F. Bistoni, A. Mencacci, E. Cenci, R. Spaccapelo, and P. Puccetti. 1996. IL-12 in C. albicans infections. Res. Immunol. 146:532–538.
12. Tonnetti, L., R. Spaccapelo, E. Cenci, A. Mencacci, P. Puccetti, R.L. Coffman, F. Bistoni, and L. R omani. 1995. Interleukin-4 and -10 exacerbate candidiasis in mice. Eur. J. Immunol. 25:1559–1565.

13. Mencacci, A., R. Spaccapelo, G. Del Sero, K.-H. Enssle, A. Cassone, F. Bistoni, and L. R omani. 1996. CD4+ T-helper cell responses in mice with low-level Candida albicans infection. Infec. Immun. 64:4907–4914.

14. Kopf, M., F. Brombacher, G. Kohler, G. Kienzle, K.-H. Widmann, K. Lefranc, C. H hungb, B. Lederman, and W. Solbach. 1996. IL-4-deficient BALB/c mice resist infection with Leishmania major. J. Exp. Med. 184:1127–1136.

15. Suzuki, Y., Q. Yang, S. Yang, N. Nguyen, S. Lim, O. Liesenfeld, T. Kojima, and J.S. Remington. 1996. IL-4 is protective against development of toxoplasmic encephalitis. J. Immunol. 157:2564–2569.

16. Roberts, C.W., D.J.P. Ferguson, H. Jebbari, A. Satoskar, H. Bluethmann, and J. Alexander. 1996. Differential roles for interleukin-4 during the course of Toxoplasma gondii infection. Infec. Immun. 64:897–904.

17. Noble, A., and D.M. Kemeny. 1995. Interleukin-4 enhances interferon-γ synthesis but inhibits development of interferon-γ-producing cells. Immunology. 85:357–363.

18. Placzek, C., G. Richer, W. Muller, H. Blocker, T. Diamant, and G. Kohler. 1992. Analysis of cytokine mRNA levels in interleukin-4-transgenic mice by quantitative polymerase chain reaction. Eur. J. Immunol. 22:1179–1184.

19. Seder, R.A., and W.E. Paul. 1994. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu. Rev. Immunol. 12:635–673.

20. Kamogawa, Y., L.E. M ina, S.R. Carding, K. Bottomly, and R.A. Flavell. 1993. The relationship of IL-4- and IFN-γ-producing T cells studied by lineage ablation of IL-4-producing cells. Cell. 75:985–995.

21. Nakamura, T., Y. Kamogawa, K. Bottomly, and R.A. Flavell. 1997. Polarization of IL-4- and IFN-γ-producing CD4+ T cells following activation of naive CD4+ T cells. J. Immunol. 158:1085–1094.

22. Nakamura, T., R.K. Lee, S.Y. Nam, E.R. Podack, K. Bottomly, and R.A. Flavell. 1997. Roles of IL-4 and IFN-γ in stabilizing the Th helper cell type 1 and 2 phenotype. J. Immunol. 158:2684–2685.

23. Kopf, M., G. Le Gros, M. Bachmann, M.C. Lamers, H. Bluethmann, and G. Kohler. 1993. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature. 362:245–248.

24. Cenci, E., A. Mencacci, R. Spaccapelo, L. Tonnetti, P. Mosci, K.-H. Enssle, P. Puccetti, L. R omani, and F. Bistoni. 1995. T helper cell type 1 (Th1) and Th2-like responses are present in mice with gastric candidiasis but protective immunity is associated with Th1 development. J. Infect. Dis. 171:1279–1288.

25. Romani, L., A. Mencacci, E. Cenci, G. Del Sero, F. Bistoni, and P. Puccetti. 1997. An immunoregulatory role for neutrophils in CD4+ Th helper subset selection in mice with candidiasis. J. Immunol. 158:2356–2362.

26. Romani, L., A. Mencacci, E. Cenci, R. Spaccapelo, G. Del Sero, I. Nicoletto, G. Trinchieri, F. Bistoni, and P. Puccetti. 1997. Neutrophil production of IL-12 and IL-10 in candidiasis and efficacy of IL-12 therapy in neutropenic mice. J. Immunol. 158:5349–5356.

27. Cenci, E., L. Romani, A. Mencacci, R. Spaccapelo, E. Schi affella, P. Puccetti, and F. Bistoni. 1993. Interleukin-4 and interleukin-10 inhibit nitric oxide-dependent macrophage killing of C. albicans. Eur. J. Immunol. 23:1034–1038.

28. Chomczynski, P., and N. Sacchi. 1987. Single-step method of R N A isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156–159.

29. Saki, R.K., S. Scharf, F. Falona, K.B. Mullis, G.T. Horn, H.A. Erlich, and N. Armheim. 1985. Enzymatic amplification of β-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science. 230:1350–1354.

30. Reiner, S.L., S. Zheng, D.B. Corry, and R.M. Locksley. 1993. Constructing polyclonal cDNA for quantitative PCR. J. Immunol. Methods. 165:37–46.

31. Djieu, J.Y. 1993. Modulators of immune responses to fungi. In Fungal Infections and Immune Responses. J.W. Murphy, H. Friedman, and M. Bendinelli, editors. Plenum Press, New York. 521–533.

32. Kullberg, B.J., J.W. van't W ant, C. Hoogstraten, and R. van Furth. 1993. Recombinant interferon-γ enhances resistance to acute disseminated C. albicans infection in mice. J. Infect. Dis. 168:436–443.

33. Romani, L., A. Mencacci, E. Cenci, R. Spaccapelo, E. Schiaffella, L. Tonnetti, P. Puccetti, and F. Bistoni. 1993. Natural killer cells do not play a dominant role in CD4+ subset differentiation in C. albicans-infected mice. Infect. Immun. 61:3769–3774.

34. Szabo, S.J., A.S. Dighe, U. Gubler, and K.M. Murphy. 1997. Regulation of the interleukin (IL)-12R β2 subunit expression in developing Th helper 1 (Th1) and Th2 cells. J. Exp. Med. 185:817–824.

35. Rogge, L., L. Barberis-M ino, M. Biffi, N. Passini, D.H. Presky, U. Gubler, and F. Sinigaglia. 1997. Selective expression of an interleukin-12 receptor component by human T helper 1 cells. J. Exp. Med. 185:825–831.

36. Hilton, D.J., J.G. Zhang, D. Metcalf, W.S. Alexander, N.A. Nicola, and T.A. Wilson. 1996. Cloning and characterization of a binding subunit of the interleukin 13 receptor that is also a component of the interleukin 4 receptor. Proc. Natl. Acad. Sci. USA. 81:7189–7193.

37. von-der-W eid, T., M. Kopf, G. Kohler, and J. Langhorne. 1994. The immune response to Plasmodium chabaudi malaria in interleukin-4-deficient mice. Eur. J. Immunol. 24:2285–2293.

38. Lawrence, R.A., J.E. Allen, W.F. Gregory, M. Kopf, and R.M. M aizels. 1995. Infection of IL-4-deficient mice with the parasitic nematode Brugia malayi demonstrates that host resistance is not dependent on a Th helper 2-dominated immune response. J. Immunol. 154:5995–6001.

39. Pearlman, E., J.H. Lass, D.S. Bardenstein, M. Kopf, F.E. Hazlett, E. Diaconu, and J.W. Kazura. 1995. IL-4 and Th2 cells are required for development of experimental onchocercal keratitis (river blindness). J. Exp. Med. 182:931–940.

40. Pearce, E.J., A. Cheever, S. Leonard, M. Covalesky, R. Fernandez-Botran, G. Kohler, and M. Kopf. 1996. Schistosoma mansoni in IL-4-deficient mice. Int. Immunol. 8:435–444.

41. Kopf, M., G. Le Gros, A.J. Coyle, M. Kosco-Vilbois, and F. Brombacher. 1995. Immune responses of IL-4-, IL-5-, IL-6-deficient mice. Immunol. Rev. 148:45–69.

42. Metwali, A., D. Elliott, A.M. Blum, J. Li, M. Sandor, R.R. Lynch, N. N oen- Trauth, and J.V. W einstock. 1996. The granulomatous response in murine Schistosomiasis mansoni does not switch to Th1 in IL-4-deficient C57BL/6 mice. J.
43. Vajdy, M., M.H. Kosko-Vilbois, M. Kopf, G. Kohler, and N. Lycke. 1995. Impaired mucosal immune responses in interleukin 4–targeted mice. J. Exp. Med. 181:41–53.
44. Mowat, A.M., and M.B. Widmer. 1995. A role for IL-4 in immunologically mediated enteropathy. Clin. Exp. Immunol. 99:65–69.
45. Stein, M., S. Keshav, N. Harris, and S. Gordon. 1992. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J. Exp. Med. 176:287–292.
46. Redmond, H., L. Schuchter, J. Shou, L.K. Hofmann, P. Leon, L. Marodi, R. Johnston, and J. Daly. 1990. Interleukin 4 (IL-4) enhances macrophage microbicidal function. J. Leukocyte Biol. 48(Suppl.):24.
47. Bobert, L.A., T.A. Waters, C.C. Pugliese-Sivo, L.M. Sullivan, S.K. Narula, and M.J. Grace. 1995. IL-4 induces neutrophilic maturation of HL-60 cells and activation of human peripheral blood neutrophils. Clin. Exp. Immunol. 99:129–136.
48. Feldman, G.M., and D.S. Finbloom. 1990. Induction and regulation of IL-4 receptor expression on murine macrophage cell lines and bone marrow–derived macrophages by IFN-γ. J. Immunol. 145:854–859.
49. Park, L., D. Friend, H. Sassenfeld, and D. Urdal. 1987. Characterization of the human B cell stimulatory factor 1 receptor. J. Exp. Med. 166:476–488.
50. Lezama-Davila, C.M., D.M. Williams, G. Gallagher, and J. Alexander. 1992. Cytokine control of Leishmania infection in the BALB/c mouse: enhancement and inhibition of parasite growth by local administration of IL-2 or IL-4 is species and time dependent. Parasite Immunol. 14:37–48.
51. D'Andrea, A., X. Ma, M. Aste-Amezaga, C. Paganin, and G. Trinchieri. 1995. Stimulatory and inhibitory effects of interleukin (IL)-4 and IL-13 on the production of cytokines by human peripheral blood mononuclear cells: priming for IL-12 and tumor necrosis factor α production. J. Exp. Med. 181:537–546.
52. Takenaka, H., S. Maruo, N. Yamamoto, M. Wysocka, S. Oono, M. Kobayashi, H. Yagita, K. Okauma, T. Hamaoka, G. Trinchieri, and H. Fujiwara. 1997. Regulation of T cell–dependent and independent IL-12 production by the three Th2-type cytokines IL-10, IL-6, and IL-4. J. Leukocyte Biol. 61:80–87.
53. Feldman, G.M., S. Ruhl, M. Bickel, D.S. Finbloom, and D.H. Pluznik. 1991. Regulation of interleukin-4 receptors on murine myeloid progenitor cells by interleukin-6. Blood. 78:1678–1684.
54. Romani, L., A. Mencacci, E. Cenci, R. Spaccapelo, C. Toniatti, P. Puccetti, F. Bistoni, and V. Poli. 1996. Impaired neutrophil response and CD4+ T helper cell development in interleukin 6–deficient mice infected with Candida albicans. J. Exp. Med. 183:1345–1355.
55. Romani, L., P. Puccetti, A. Mencacci, R. Spaccapelo, E. Cenci, L. Tonnetti, and F. Bistoni. 1994. Tolerance to staphylococcal enterotoxin B initiates Th1 cell differentiation in mice infected with Candida albicans. Infec. Immun. 62:4047–4053.
56. Romani, L., and D.H. Howard. 1995. Mechanisms of resistance to fungal infections. Curr. Opin. Immunol. 7:517–523.
57. Reiner, S.L., S. Zheng, Z.-E. Wang, L. Stowring, and R.M. Locksley. 1994. Leishmania promastigotes evade interleukin-12 (IL-12) induction by macrophages and stimulate a broad range of cytokines from CD4+ T cells during initiation of infection. J. Exp. Med. 179:447–456.
58. Launois, P., T. Ohteki, K. Swihart, H.R. MacDonald, and J.A. Louis. 1995. In susceptible mice Leishmania major induces very rapid interleukin-4 production by CD4+ T cells which are NK1.1–. Eur. J. Immunol. 25:3298–3307.